invega
janssen-cilag pty ltd - paliperidone -
minims artificial tears 0.35% w/w + 0.44% w/w eye 0.35 + 0.4 %w/w eye drops solution
chauvin pharmaceuticals limited - sodium chloride hydroxyethylcellulose - eye drops solution - 0.35 + 0.4 %w/w
minims artificial tears 0.35% w/w + 0.44% w/w eye drops, solution
bausch health ireland limited - sodium chloride; hydroxyethylcellulose - eye drops, solution - 0.35% w/w + 0.44 percent weight/weight - other antiinfectives; sodium borate
minims artificial tears 0.35% w/w + 0.44% w/w eye drops, solution
bausch + lomb ireland limited - sodium chloride; hydroxyethylcellulose - eye drops, solution - other antiinfectives; sodium borate
phyllocontin continus 225 mg prolonged release tablets
mundipharma pharmaceuticals limited - aminophylline hydrate - prolonged-release tablet - 225 milligram(s) - xanthines; aminophylline
phyllocontin continus 225 mg prolonged release tablets
ennogen healthcare (europe) limited - aminophylline hydrate - prolonged-release tablet - xanthines; aminophylline
arrow - morphine la
teva pharma (new zealand) limited - morphine sulfate pentahydrate 100mg - modified release tablet - 100 mg - active: morphine sulfate pentahydrate 100mg excipient: hyetellose hypromellose magnesium stearate opadry grey oy-8238 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.
arrow - morphine la
teva pharma (new zealand) limited - morphine sulfate pentahydrate 10mg - modified release tablet - 10 mg - active: morphine sulfate pentahydrate 10mg excipient: hyetellose hypromellose lactose monohydrate magnesium stearate opadry buff oy-3607 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.
arrow - morphine la
teva pharma (new zealand) limited - morphine sulfate pentahydrate 30mg - modified release tablet - 30 mg - active: morphine sulfate pentahydrate 30mg excipient: hyetellose hypromellose lactose monohydrate magnesium stearate opadry violet 0y-6708 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.
arrow - morphine la
teva pharma (new zealand) limited - morphine sulfate pentahydrate 60mg - modified release tablet - 60 mg - active: morphine sulfate pentahydrate 60mg excipient: hyetellose hypromellose lactose monohydrate magnesium stearate opadry orange oy-3533 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.